BRAF and melanoma: Results: The background for the authorisation of nivolumab in the treatment of subjects with advanced melanoma were two different studies: study CA209037 [2, 3]: a phase 3 trial of nivolumab vs investigator’s choice in advanced Melanoma patients progressing post anti-CTLA-4 therapy; and Study CA209069 [2, 4]: a phase 3, study of nivolumab vs dacarbazine in subjects with BRAF wild type, previously untreated.